2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 10, 2015

9:00AM-11:00AM: Abstract Number: 2297

Dinamyx Neuromodulation in Fibromyalgia

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster II

9:00AM-11:00AM: Abstract Number: 2863

Discontinuation of Anti-TNF Therapy in Patients with Axial Spondyloarthritis. a Systematic Literature Review

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster III: Therapy

9:00AM-11:00AM: Abstract Number: 2689

Discrepancies Between Patients and Physicians in Their Perceptions of Rheumatoid Arthritis Disease Activity Are Multifactorial in Early Rheumatoid Arthritis

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2839

Disease Activity and Safety during Long-Term (104-Week) Treatment with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster III: Therapy

9:00AM-11:00AM: Abstract Number: 2532

Disease Activity in Women with Systemic Lupus Erythematosus during Pregnancy and the First Year Post Partum

Reproductive Issues in Rheumatic Disorders: Basic and Clinical Aspects Poster Session

9:00AM-11:00AM: Abstract Number: 2927

Disease Activity Patterns over Time in Patients with SLE – a Retrospective Descriptive Analysis of the Hopkins Lupus Cohort

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

9:00AM-11:00AM: Abstract Number: 2626

Disease Activity Predicts ABCB1 and ABCG2 Drug-Efflux Transporters Function in Rheumatoid Arthritis (RA) Patients

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2935

Disease Evolution in Late Onset and Early Onset Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

9:00AM-11:00AM: Abstract Number: 2788

DNA Microarray Analysis of Labial Salivary Glands in Patients with Sjögren’s Syndrome: Comparison with IgG4-Related Disease

Sjögren's Syndrome: Translational Insights into Sjögren's Syndrome

9:00AM-11:00AM: Abstract Number: 2918

Do Patients with Lupus Nephritis Who Achieve Complete Proteinuria Recovery at 2 Years Have Better Long Term Outcomes Compared to Patients with Partial Proteinuria Recovery?

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

9:00AM-11:00AM: Abstract Number: 2327

Documentation of Clinical Improvement in Patient with Polymyalgia Rheumatica According to MDHAQ/RAPID3 (Multidimensional Health Assessment Questionnaire/Routine Assessment of Patient Index Data): Longitudinal Analysis from Routine Care

Health Services Research Poster III: Patient Reported Outcomes, Patient Education and Preferences

9:00AM-11:00AM: Abstract Number: 2491

Documentation of Disease Activity Score As Part of a Treat to Target Strategy in Rheumatoid Arthritis

Quality Measures and Quality of Care Poster Session

9:00AM-11:00AM: Abstract Number: 2627

Does 14-3-3 ETA Protein Offer Any Additional Diagnostic Value in Rheumatoid Arthritis?

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2478

Does Affect Predict Willingness to Take Medication?

Psychology/Social Sciences (ARHP)

9:00AM-11:00AM: Abstract Number: 2449

Does Antinuclear Antibodies Predict Remission in JIA ?

Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters (ACR): Imaging and Novel Clinical Interventions

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].